US3922261A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Adenosine derivative
Assignee: Merck Patent GmbH
•
Filing: 1973-06-20
•
Granted: 1975-11-25
•
Expires: 1993-06-20
Abstract
Abstract N6-(1,2,3,4-tetrahydronaphthyl-2)-adenosine has valuable pharmaceutical properties, and is useful in reducing the serum concentration of free fatty acids and triglycerides and selectively improving coronary blood circulation.
Inventors
- 👤 Rolf Pohlke
- 👤 Werner Mehrhof
- 👤 Karl-Heinz Becker
- 👤 Hans-Jochen Schliep
- 👤 Herbert Nowak
- 👤 Zdenek Simane
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 17:46
CPC Classifications
C; C07; C07H; C07H19/00; C07H19/02; C07H19/04; C07H19/16
Claims Analysis
Total Claims: 3
Claim 1
Independent Claim
29 words
A MEMBER OF THE GROUP CONSISTING OF N6-(1,2,3,4-TETRAHYDRONAPHTHYL-2-)-ADENOSINE, THE OPTICAL ISOMER THEREOF HAVING A MELTING POINT OF 164*-166*C. AND THE OPTICAL ISOMER THEREOF HAVING A MELTING POINT OF 175*-176*C.
Claim 2
Dependent Claim
29 words
A MEMBER OF THE GROUP CONSISTING OF N6-(1,2,3,4-TETRAHYDRONAPHTHYL-2-)-ADENOSINE, THE OPTICAL ISOMER THEREOF HAVING A MELTING POINT OF 164*-166*C. AND THE OPTICAL ISOMER THEREOF HAVING A MELTING POINT OF 175*-176*C.
Claim 3
Dependent Claim
17 words
A compound of claim 1, the optical isomer of N6-(1,2,3,4-tetrahydronaphthyl-2-)-adenosine having a melting point of 164*-166* C.
References Cited (Backward Citations)
US3796700A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1978-11-24 | 1979-05-26 | 1979-11-25 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1982-11-24 | 1983-05-26 | 1983-11-25 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1986-11-24 | 1987-05-26 | 1987-11-25 | $7700.00 | Window Closed / Lapsed |